

PHAYM001: Preparation for professional practice

[View Online](#)

1.

Maier AR. Efficacy and Comparative Effectiveness of Atypical Antipsychotic Medications for Off-Label Uses in Adults: A Systematic Review and Meta-analysis. JAMA: The Journal of the American Medical Association. 2011;306(12). doi:10.1001/jama.2011.1360

2.

Clinical guidelines, CG42 - Issued: November 2006. <http://guidance.nice.org.uk/CG42>

3.

TA217 Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine: guidance (MS Word format). <http://guidance.nice.org.uk/TA217/Guidance/doc/English>

4.

Exelon - Summary of Product Characteristics (SPC) - (eMC).
<https://www.medicines.org.uk/emc/search?q=Exelon+>

5.

Aricept Tablets - Summary of Product Characteristics (SPC) - (eMC).
<http://www.medicines.org.uk/emc/medicine/577/SPC/Aricept>

6.

Reminyl Tablets - Summary of Product Characteristics (SPC) - (eMC).

7.

Ebixa 5mg/pump actuation oral solution, 20mg and 10 mg Tablets and Treatment Initiation Pack - Summary of Product Characteristics (SPC) - (eMC).

<http://www.medicines.org.uk/EMC/medicine/10175/SPC/rEbixa+5mg+pump+oral+solution%252c+20mg+and+10+mg+tablets+and+Treatment+Initiation+Pack/>

8.

DH Living well with dementia: a National Dementia Strategy.

<https://www.gov.uk/government/organisations/department-of-health>

9.

British National Formulary. <http://www.bnf.org/bnf/index.htm>

10.

Bhasin M, Rowan E, Edwards K, McKeith I. Cholinesterase inhibitors in dementia with Lewy bodies—a comparative analysis. *International Journal of Geriatric Psychiatry*. 2007;22(9):890-895. doi:10.1002/gps.1759

11.

Kavirajan H, Schneider LS. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. *The Lancet Neurology*. 2007;6(9):782-792. doi:10.1016/S1474-4422(07)70195-3

12.

Warner J, Smith T. The rise and fall of antipsychotic prescribing in dementia. Where do we go from here? *The rise and fall of antipsychotic prescribing in dementia*. 14(2):24-27.

13.

Sube Banerjee. The use of antipsychotic medication for people with dementia: Time for action. A report for the Minister of State for Care Services. Published online 12 AD.

<http://psychrights.org/research/digest/nlps/BanerjeeReportOnGeriatricNeurolepticUse.pdf>

14.

Optimising treatment and care for behavioural and psychological symptoms of dementia: A best practice guide. <https://www.alzheimers.org.uk/bpsdguide>

15.

Treatment protocol by NHS Medway: Treatment of Behaviour That Challenges.
<http://www.kmpt.nhs.uk/policies>

16.

Antipsychotics increase mortality in elderly patients with dementia.
http://www.npc.nhs.uk/merec/cns/dementia/merec_extra_no39.php

17.

Electronic Medicines Compendium (eMC). <http://www.medicines.org.uk/emc/>

18.

Pierre N. Tariot, M.D.; Rosemary Erb, R.N., B.S.N.; Carol Ann Podgorski, Ph.D.; Christopher Cox, Ph.D.; Shirish Patel, M.D.; Laura Jakimovich, M.S., R.N.; Carrie Irvine, B.A. Efficacy and Tolerability of Carbamazepine for Agitation and Aggression in Dementia. *PsychiatryOnline | American Journal of Psychiatry* | Efficacy and Tolerability of Carbamazepine for Agitation and Aggression in Dementia. 1998;155(1):54-61. doi:10.1176/ajp.155.1.54

19.

Martinón-Torres G, Fioravanti M, Grimley Evans J. Trazodone for agitation in dementia. *Cochrane Database of Systematic Reviews*. Published online 19 July 2004. doi:10.1002/14651858.CD004990

20.

Electronic Medicines Compendium (eMC). <http://www.medicines.org.uk/emc/>

21.

Risperdal Tablets, Liquid & Quicklet - Summary of Product Characteristics (SPC) - (eMC).
<http://www.medicines.org.uk/emc/document.aspx?documentid=12818&docType=SPC>

22.

Maher AR, Maglione M, Bagley S, et al. Efficacy and Comparative Effectiveness of Atypical Antipsychotic Medications for Off-Label Uses in Adults. JAMA. 2011;306(12).
doi:10.1001/jama.2011.1360

23.

Complete Guide to Behavioural and Psychological symptoms of Dementia.
<http://www.ipa-online.org/>

24.

Waldemar G, Hyvärinen M, Josiassen MK, Kørner A, Lehto H, Wetterberg P. Tolerability of switching from donepezil to memantine treatment in patients with moderate to severe Alzheimer's disease. International Journal of Geriatric Psychiatry. 2008;23(9):979-981.
doi:10.1002/gps.1979

25.

Electronic Medicines Compendium (eMC). <https://www.medicines.org.uk/emc/>

26.

Evidence Search - Search Engine for Evidence in Health and Social Care.
<https://www.evidence.nhs.uk/>

27.

Evidence Search - Search Engine for Evidence in Health and Social Care.

<https://www.evidence.nhs.uk/>

28.

Map of Medicine | Home. <http://www.mapofmedicine.com/>

29.

Medicines Information - Evidence Search - Search Engine for Evidence in Health and Social Care. <https://www.evidence.nhs.uk/>

30.

NPC | National Prescribing Centre. <https://www.guidelinesinpractice.co.uk>

31.

National Institute for Health and Care Excellence. <http://www.nice.org.uk/>

32.

NICE Clinical Knowledge Summaries (CKS). <http://cks.nice.org.uk/>

33.

Scottish Intercollegiate Guidelines Network (SIGN). <http://www.sign.ac.uk/>

34.

Centre for Medicines Optimisation - MTRAC | Independent Medicines Review | Midlands Therapeutics Review & Advisory Committee | Centre for Medicines Optimisation | Keele University. <http://centreformedicinesoptimisation.co.uk/mtrac/>

35.

NPC | National Prescribing Centre. <https://www.guidelinesinpractice.co.uk>

36.

Evidence Search - Search Engine for Evidence in Health and Social Care.
<https://www.evidence.nhs.uk/>

37.

GOV.UK. <https://www.gov.uk/government/organisations/department-of-health>

38.

Miller WR, Rollnick S. Motivational Interviewing: Helping People Change. Vol Applications of motivational interviewing. 3rd ed. Guilford Press; 2013.

39.

Prochaska JO, Norcross JC, DiClemente CC. Changing for Good. William Morrow; 1994.

40.

Rollnick S, Mason P, Butler C. Health Behavior Change: A Guide for Practitioners. Churchill Livingstone; 1999.

41.

Rollnick S, Miller WR, Butler C. Motivational Interviewing in Health Care: Helping Patients Change Behavior. Vol Applications of motivational interviewing. Guilford Press; 2008.

42.

Hubley J, Copeman J, Woodall J. Practical Health Promotion. 2nd ed. Polity Press; 2013.

43.

Laverack G. Health Promotion Practice: Building Empowered Communities. Open University Press; 2007.

<https://search.ebscohost.com/login.aspx?direct=true&AuthType=ip,shib&db=nlebk&AN=234222&site=ehost-live&scope=site&custid=s8454451>

44.

Macdowall W, Bonell C, Davies M. Health Promotion Practice. Vol Understanding public health. Open University Press; 2006.

45.

Walker R, Whittlesea C. Clinical Pharmacy and Therapeutics. 5th ed. Churchill Livingstone; 2012. <https://www.vlebooks.com/Product/Index/173020?page=0&startBookmarkId=-1>

46.

Kumar PJ, Clark ML. Kumar & Clark's Clinical Medicine. 8th ed. Saunders Elsevier; 2012. <https://www.dawsonera.com/abstract/9780702053047>

47.

Greene RJ, Harris ND. Pathology and Therapeutics for Pharmacists: A Basis for Clinical Pharmacy Practice. 3rd ed. Pharmaceutical Press; 2008.

48.

Coeliac disease: recognition, assessment and management | Guidance and guidelines | NICE. <https://www.nice.org.uk/guidance/ng20>

49.

Chronic obstructive pulmonary disease.
<http://cks.nice.org.uk/chronic-obstructive-pulmonary-disease>

50.

CPPE - Centre for Pharmacy Postgraduate Education. <https://www.cppe.ac.uk/>

51.

Royal Pharmaceutical Society (RPS). <http://www.rpharms.com/home/home.asp>

52.

Heart failure - chronic. <http://cks.nice.org.uk/heart-failure-chronic>

53.

Medicines Use Review and Prescription Intervention service.
http://psnc.org.uk/wp-content/uploads/2013/06/MUR-service-spec-Aug-2013-changes_FINAL.pdf

54.

Service specification - New Medicine Service (NMS).
http://psnc.org.uk/wp-content/uploads/2013/06/NMS-service-spec-Aug-2013-changes_FINAL.pdf

55.

Commissioners and healthcare professionals - Training videos.
http://healthcheck.nhs.uk/commissioners_and_providers/training/training_videos1/

56.

NHS Health Check - NHS Choices.
<http://www.nhs.uk/Conditions/nhs-health-check/Pages/NHS-Health-Check.aspx>